Replies to post #150553 on Biotech Values

[Caoi]

I have a few questions about AEZS

1) Perifisone has failed once what chance do you give make it through trials and ultimately to market ?
The company operates at a loss of almost 8 million a quarter.

2) What is your opinion of AEZS-108 ? I guess that is what Roth is so hopeful about.Mid November they will hear if they receive a special protocol assessment.

3) The company just did a reverse split and diluted the stock.
The market spoke loudly.Are they done financing ?

It does look like a falling knife.

I personally would view it as a lotto play but i would wait for it to stabilize.

I am very curious if you have any more in-depth insight into the company.

Thanks